Showing 3551-3560 of 4262 results for "".
- Study Uncovers How B Cells React to Melanomahttps://practicaldermatology.com/news/study-uncovers-how-b-cells-react-to-melanoma/2461773/Antibody-producing B cells may be defective in responding to melanoma, a new study suggests. The study is published in Nature Communications. Researchers used advanced technologies to delve into the antibody immune response in blood and tissues of patients with m
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i
- Programmable 3D-printed Wound Dressing Could Improve Treatment for Burns and Aid Drug Deliveryhttps://practicaldermatology.com/news/programmable-3d-printed-wound-dressing-could-improve-treatment-for-burns-and-aid-drug-delivery/2461762/A 3D-printed wound dressing that uses advanced polymers may enhance the healing process for burn patients, aid drug delivery in cancer treatment, and help customize skin care regimens. "To treat burn victims, we can customize the shape using a 3D printer, secondly, t
- EULAR News: Amgen's Otzela Cools Inflammation, May Improve CV Health in PsAhttps://practicaldermatology.com/news/eular-news-amgens-otzela-cools-inflammation-may-improve-cv-health-in-psa/2461749/Otezla (apremilast) showed promising results in cooling inflammation and reducing cardiometabolic risk factors in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), in Milan, Italy. The MOSAIC Phase
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiativehttps://practicaldermatology.com/news/stony-brook-university-hospital-and-the-mollie-biggane-melanoma-foundation-promote-skin-cancer-prevention-through-new-inpatient-initiative/2461709/Stony Brook University Hospital (SBUH) and the Mollie Biggane Melanoma Foundation announce a collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program, according to a news release. Historicall
- Study: DecisionDx-Melanoma May Lead to Earlier Melanoma Detection, Decreased Metastatic Tumor Burdenhttps://practicaldermatology.com/news/study-decisiondx-melanoma-may-lead-to-earlier-melanoma-detection-decreased-metastatic-tumor-burden/2461698/The use of Castle Biosciences, Inc. DecisionDx-Melanoma test results to guide radiological surveillance may lead to improved patient outcomes, according to a new study in Archives of Dermatological Research. The new study, conducted at three National Cancer Institute-desig
- Resilia Pharmaceuticals Announces Return to Market of Neosalus Cream and Neosalus Lotionhttps://practicaldermatology.com/news/resilia-pharmaceuticals-announces-return-to-market-of-neosalus-cream-and-neosalus-lotion/2461697/Resilia Pharmaceuticals, Inc.’s Neosalus Cream and Neosalus Lotion are back. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Both Neosalus Lotion and Neosalus Cream use paten
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing